Clinical Scorecard: Cognitive and Brain Imaging Changes Over Time in Individuals Living with HIV
At a Glance
Category
Detail
Condition
HIV-associated cognitive impairment and brain volume changes
Key Mechanisms
Impact of HIV viral load and aging on cognition and brain structural integrity
Target Population
Persons with HIV (PWH) with detectable and undetectable viral loads, and people without HIV (PWOH)
Care Setting
Clinical and research settings involving neurocognitive assessment and neuroimaging
Key Highlights
PWH with undetectable viral load (PWHU) show similar cognitive aging trajectories and brain volume changes as PWOH.
PWH with detectable viral load (PWHD) exhibit accelerated cognitive decline and smaller regional brain volumes, especially in lentiform regions.
Viral suppression is critical to prevent accelerated cognitive decline and brain volume loss in aging PWH.
Guideline-Based Recommendations
Diagnosis
Use cognitive testing batteries assessing learning, memory, executive function, psychomotor speed, and verbal fluency.
Incorporate neuroimaging to evaluate structural brain integrity, focusing on regional brain volumes.
Classify PWH by viral load status (≤50 copies/mL undetectable; >50 copies/mL detectable) for risk stratification.
Management
Maintain viral suppression through effective antiretroviral therapy to reduce risk of accelerated cognitive decline.
Monitor cognitive function regularly in PWH, especially those with detectable viral loads.
Address comorbidities and exclude confounding neurological or psychiatric conditions.
Monitoring & Follow-up
Longitudinal cognitive assessments using standardized composite scores (e.g., NPZ4).
Periodic brain imaging to track regional volume changes, particularly in lentiform regions.
Regular viral load testing to ensure continued suppression.
Risks
Detectable HIV viral load increases risk for accelerated cognitive decline and brain volume loss.
Aging combined with unsuppressed HIV may exacerbate neurocognitive impairment.
Failure to achieve or maintain viral suppression may lead to progressive neurocognitive disorders.
Patient & Prescribing Data
Persons with HIV on antiretroviral therapy, stratified by viral load detectability
Achieving and maintaining viral suppression (HIV RNA ≤50 copies/mL) is associated with cognitive and brain volume trajectories comparable to HIV-negative individuals.
Clinical Best Practices
Screen PWH regularly for cognitive impairment using validated neuropsychological tests.
Incorporate viral load measurements to guide risk assessment and management.
Use neuroimaging adjunctively to understand structural brain changes and tailor interventions.
Prioritize adherence to ART to maintain viral suppression and protect cognitive function.
Consider longitudinal monitoring to detect early cognitive decline and intervene promptly.
